Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | RHEB | Q15382 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577125 | 0.89 | CCR2 (0.33) | — | |
| SCHEMBL5577131 | 0.84 | GABRA1 (0.35) | GABRA1GABRG2GABRB3GABRA5RHEB | |
| SCHEMBL5576641 | 0.79 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA5RHEB | |
| SCHEMBL5577104 | 0.75 | KDM4E (0.39) | GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5234417 | 0.74 | ADORA1 (0.38) | — | |
| SCHEMBL5576340 | 0.73 | CCR2 (0.46) | — | |
| SCHEMBL5237348 | 0.70 | DPP4 (0.40) | — | |
| SCHEMBL5576873 | 0.69 | DPP4 (0.36) | — | |
| SCHEMBL5235402 | 0.69 | PTGS1 (0.36) | — | |
| SCHEMBL5233243 | 0.69 | PLA2G2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | GABRA1 367/4885GABRG2 473/4885GABRB3 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.